Samsung Bioepis Confident Eylea And Lucentis Biosimilars Can Coexist

Korea-Based Firm’s Phase III Aflibercept Data Expected This Year

 
• By Dean Rudge
Eye
Biosimilars to Lucentis may launch this year, with Eylea biosimilars expected to follow in 2023. • Source: Shutterstock

More from Biosimilars

More from Products